The three essential levels in cancer care (prevention, treatment and monitoring of the disease) can help beat cancer for good. And the technologies listed in this article are separated according to these phases.
Cancer-related biopsychosocial distress is highly prevalent across the cancer care continuum. The implementation of screening patients for biopsychosocial distress has become a standard of practice in cancer care. With the presence of COVID-19, clinical care has shifted from in-person care to virtual care in many instances. One of the realities of COVID-19 is the significant decrease in screening patients for biopsychosocial symptom burden. Given the presence of COVID-19, much of cancer care has shifted to being delivered virtually (through mediums such as Zoom). This paper presents pre- and post-COVID data on the frequency of distress screening and its impact on patient care.
The authors are looking at those technologies in digital health that are on a certain ‘hype cycle’ – technologies and solutions that currently stand out from the rest because of their novelty, timeliness, or greatness. The article series begins with skin checking algorithms, which is definitely a course currently rising.
Oncology practices will now be able to order and track Foundation Medicine, Inc.’s comprehensive genomic profiling (CGP) tests for their patients without leaving Flatiron Health’s OncoEMR® platform, the two companies announced today. This integration, the first of a series planned by Flatiron, will support more efficient clinical decision making by allowing electronic ordering, order tracking and receipt of Foundation Medicine’s CGP test results all within the OncoEMR platform. The two companies are planning similar integrations with other CGP platforms and EMRs, respectively, in the oncology space, with the goal of helping every patient to realize the benefit of precision cancer care.
#connected device
#platform
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) virtual congress, taking place June 9-17.
Israel-based startup OncoHost, the developer of a blood test to predict how well cancer patients will react to treatment, said it will collaborate with the National Health Service (NHS) to set up eight clinical trial sites in the United Kingdom. The trials will focus on patients diagnosed with advanced stages of melanoma or non-small cell lung cancer (NSCLC), aiming to predict their response to immunotherapy treatment. The new trial sites will join OncoHost’s ongoing study, which uses the company’s host response profiling platform, called PROphet.
The story of Ric Grenell and his cancer battle, which led to the creation of Wave App, was Featured on Newsmax TV’s morning news show, Wake Up America. Check out the in-depth interview with a real Wave App user (Carol) and learn how Wave has helped her take control of her health while fighting cancer.
IQVIA Report which shares the digital health trends in 2021 has featured Mika app as one of the digital care tools specifically targetting cancer patients that is also approved by DiGA and CE Mark. According to the report, Digital therapeutics (DTx) and digital care (DC) products and tools — which incorporate software as a means to treat, prevent or manage specific diseases or conditions — have been proliferating, and more than 250 such products are now identified, including about 150 products that are commercially available.
The MedTech 50 celebrates businesses helping to diagnose and treat conditions, mainly in a clinical setting such as a hospital, and other biotechnology companies and Vinehealth is excited to be ranked #12 by BusinessCloud.
Vinehealth is the winner of the THE EUROPAS 2021 in the Hottest HealthTech Startup category.